Insights

Taimei Expert Insights | What Exactly Does the FDA's Real-Time Clinical Trials Pilot Aim to Achieve?

AI Translation


Summary: The FDA's attempt at Real-Time Clinical Trials (RTCT) is more like changing clinical trials from "submitting the final exam paper" to "taking pop quizzes." It no longer waits until the clinical trial is over to package, clean, analyze, and submit data step by step, but instead transmits the most critical efficacy and safety data back to regulators in real time during the trial, achieving "full-process oversight."

 

The pharmaceutical industry has never stopped trying to compress clinical development cycles. Therefore, when the FDA's press release on RTCT was made public on April 28, it quickly attracted the attention of many industry practitioners.

Although real-time clinical trials are not simply opening a "data livestream" for regulators, nor are they allowing patient privacy data to "run naked" in the cloud, the FDA is attempting to compress the long-standing waiting, transcription, repeated organization, and gaps between stages in clinical research into a shorter, more controllable pathway.

To put it more simply: kill risks in the bud whenever possible.

For sponsors, CROs, research sites, and even hospital IIT research projects, this is not a distant overseas news item. What it points to is a common issue in the digital capabilities of clinical research: Can data be seen earlier? Can risks be identified earlier? Can quality be managed during the process, rather than "making up homework" only at the end?

 

01: What did the FDA say in its press release?

According to the FDA press release issued on April 28, 2026, this real-time clinical trials pilot mainly consists of two parts:

1. Two proof-of-concept real-time clinical trials have been launched, from AstraZeneca and Amgen respectively. The relevant trials will report endpoint indicators and data signals to the FDA in real time.

2. The FDA issued a Request for Information (RFI) to solicit comments on the real-time clinical trials pilot program planned to launch this summer.

The FDA disclosed that it has received and verified signals from AstraZeneca's trial through Paradigm Health, thereby proving the feasibility of the technical framework required for real-time signal sharing.

 

02: What time can RTCT actually save?

Clinical trials have an endless pursuit of the completeness and reliability of the evidence chain. Once data are found to be "unclean, inconsistent, and untraceable" only at the end of the trial, remediation is not only costly but also greatly prolongs the trial cycle.

In reports on the press conference, multiple media outlets also mentioned that FDA Commissioner Marty Makary referred to the large number of waiting steps in clinical development, such as administrative work, paperwork, and data organization, as "dead time."

What real-time clinical trials aim to solve is making "dead time" as short as possible.

The FDA emphasized that the current pilot focuses on predefined safety and efficacy signals, rather than giving regulators direct access to all patient-level source records. Reuters also reported that the FDA receives aggregated signals, such as adverse reaction rates or tumor response proportions, while individual patient records remain with the trial-related parties.

 

03: Does this affect clinical research in China?

A clinical research digital intelligence expert from Taimei Technology stated that RTCT is not simply "moving" traditional processes "to the cloud," but requires that data standards, signal definitions, trigger rules, traceability logic, and permission boundaries be clearly designed at the front end of the trial. Moreover, in the short term, the RTCT pilot remains an exploration under the U.S. regulatory system and does not mean that all domestic registration studies or IIT projects must immediately copy it.

However, the expert also cautioned that the change in regulatory thinking reflected by TRCT—from "result management" to "process management"—means that data should have quality control capability at the time of collection, risk detection capability during operation, and interpretability, traceability, and exportability before completion.

To improve this capability, whether for new drug registration clinical research or IIT research projects conducted by medical institutions themselves, it is necessary to unswervingly improve the level of digital intelligence development.

 

04: From EDC to IWRS, digital intelligence technology remains the cornerstone of "process management"

In the past, when many people talked about the digitalization of clinical research, such as EDC, their first reaction was "moving paper CRFs onto computers." But judging from the signals released by the FDA's real-time clinical trials, the value of digitalization in clinical research is changing:

l From "post hoc organization" to "in-process quality control";

l From "data collection" to "signal identification";

l From "manual progress tracking" to "system-based risk monitoring";

l From "analysis after project completion" to "continuous judgment during ongoing research";

l Moving from "single-point tools" to "coordination of EDC, IWRS, follow-up, data management center, and statistical analysis."

If clinical trials are understood as a data chain, EDC is responsible for collecting research data in a structured, quality-controlled, and traceable manner; the IWRS/randomization system is responsible for managing key processes such as subject randomization, stratification, blinding, and unblinding in a rule-based and traceable way.

Taking hospital research scenarios as an example, a mature research data collection platform should at least help research teams solve several types of problems:

l Whether forms can be flexibly configured according to the research protocol, avoiding research design being constrained in reverse by tools;

l Whether visits, follow-ups, and unscheduled data can be managed according to workflow, rather than relying on manual reminders;

l Whether automatic logic checks can be performed during data entry, reducing centralized cleaning at the end;

l Whether queries can be initiated, responded to, and closed online, forming a closed loop;

l Whether key operations have permission control, electronic signatures, and audit trails;

l Whether data can be flexibly exported according to statistical, manuscript submission, archiving, and regulatory/ethics requirements.

Taimei Technology has long focused on digital and intelligent clinical research scenarios and has a comprehensive AI-driven end-to-end clinical development solution and AI Agent matrix, such as IIT-EDC, eBalance (RTSM), subject screening data platform, and integrated clinical research management platform, helping clinical research workers achieve digitalized and standardized management across the entire process from institutional management, data management, randomization management, to patient screening, and meet international-level compliance requirements.

He also has his own views on the impact of real-time clinical trials on digital and intelligent development.

"The ultimate goal of digitalizing clinical research is not to add another system entry point, but to make research quality more controllable, research efficiency more visible, and research results more credible. What truly creates the quality gap in clinical trials is often not the final report, but whether the research team has embedded data quality into the system from the first subject, the first CRF, the first randomization, and the first query."

 

——Clinical Research Digitalization Expert at Taimei Technology

 

Final Notes:

The FDA's real-time clinical trials pilot is only an attempt and still has many problems, but for domestic clinical research it is a trend worth learning about in advance. Because clinical trials may not immediately enter the "live broadcast era," but they will very likely bid farewell to the era of "problems only discovered at the end."

For digital and intelligent development, the best starting point was 10 years ago, and the next best is now.

 

Data Sources and References

[1] FDA News Release: FDA Announces Major Steps to Implement Real-Time Clinical Trials

https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials

[2] FDA GovDelivery: FDA Announces Major Steps to Implement Real-Time Clinical Trials (including Chinese translation reference)

https://content.govdelivery.com/accounts/USFDA/bulletins/415045f

[3] Federal Register: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information

https://www.federalregister.gov/documents/2026/04/29/2026-08281/ai-enabled-optimization-of-early-phase-clinical-trials-pilot-program-request-for-information

[4] Fierce Biotech: FDA unveils plan for real-time review of clinical trial data

https://www.fiercebiotech.com/biotech/fda-unveils-plan-real-time-review-clinical-trial-data-astrazeneca-and-amgen-already-board

[5] Taimei Technology internal product materials: IIT-EDC scientific research data collection system, eBalance (RTSM) randomization and drug supply system, Taimei Technology company introduction